Overview

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Status:
Active, not recruiting

Trial end date:
2022-05-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).

Phase:

Phase 3

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Everolimus
Imatinib Mesylate
Infliximab
Methotrexate
Mycophenolate mofetil
Mycophenolic Acid
Pentostatin
Rituximab
Sirolimus